The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more ...

Company receives expanded access protocol authorization from the U.S. Food and Drug Administration (FDA) for troculeucel granted to treat patients with known diagnoses of multiple neurodegenerative ...

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolde ...

The Global Neurodegeneration Proteomics Consortium (GNPC) has published a series of research papers detailing their efforts ...

I want to eat” popped up in Chinese characters on a computer at a public hospital in central Beijing. The words were formed ...